CPC H04R 3/005 (2013.01) [A61K 9/5026 (2013.01); A61K 9/5031 (2013.01); A61K 9/5073 (2013.01); A61K 9/5089 (2013.01); A61K 38/39 (2013.01); A61K 38/47 (2013.01); A61K 49/04 (2013.01); C12Y 304/22032 (2013.01); C12Y 304/22033 (2013.01); G10L 21/0232 (2013.01); G10L 21/028 (2013.01); H04R 3/04 (2013.01); H04R 5/04 (2013.01); G10L 2021/02166 (2013.01)] | 21 Claims |
1. An implantable device for delivery of a macromolecular drug compound, the device comprising:
a core having an outer surface, wherein the core comprises a core polymer matrix within which is dispersed a drug compound having a molecular weight of about 0.5 kDa or more, the polymer matrix containing a first ethylene vinyl acetate copolymer; and
a membrane layer positioned adjacent to the outer surface of the core, wherein the membrane layer comprises a membrane polymer matrix within which the macromolecular drug compound is optionally dispersed, wherein the membrane polymer matrix contains a second ethylene vinyl acetate copolymer in combination with a hydrophilic compound, wherein the weight ratio of the second ethylene vinyl acetate copolymer to the hydrophilic compound within the membrane polymer matrix ranges from at least about 2.3 to about 99.
|